Compared to monotherapy, combining OSMI-4 with the anti-PD-L1 mAb presents a synergistic inhibitory effect on the growth of hepatocellular carcinoma (HCC) and melanoma [6]. Here, CD274 is linked to hepatocellular carcinoma.